<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00355056</url>
  </required_header>
  <id_info>
    <org_study_id>AGA-010</org_study_id>
    <nct_id>NCT00355056</nct_id>
  </id_info>
  <brief_title>PREMIUM Migraine Trial</brief_title>
  <official_title>Prospective, Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this study is to evaluate the impact of percutaneous closure of a patent&#xD;
      foramen ovale (PFO) (a hole in the heart), using the AMPLATZER PFO Occluder, on the incidence&#xD;
      of migraine headaches.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate whether percutaneous PFO closure is effective in&#xD;
      reducing the incidence of disabling migraine headaches in patients who are refactory to&#xD;
      medical treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint - Percentage of Subjects With a 50% Reduction From Baseline in the Monthly Number of Migraine Attacks at 12 Months.</measure>
    <time_frame>Baseline and months 10-12</time_frame>
    <description>A 50% reduction from the monthly number of migraine attacks during the 60-day baseline phase to the monthly number of migraine attacks during month ten through the twelfth month in the treatment phase (device group versus sham group).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint - Device Related Serious Adverse Event (SAE)</measure>
    <time_frame>Baseline through 12 months</time_frame>
    <description>Number of subjects who experience a device-related major adverse event (DRMAE) through 12-months of follow-up.&#xD;
This endpoint was analyzed using an as-treated cohort that consists of all enrolled subjects who received the device (randomized and Optional PFO Closure group) and who had follow-up sufficient to adequately assess the DRMAE rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Migraine Days/Month</measure>
    <time_frame>Baseline and months 10-12</time_frame>
    <description>Change in the number of migraine days is calculated by the difference in the mean number of migraine days between the baseline assessment period and the treatment phase (months 10-12 post-procedure) for the respective randomization groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Successful PFO Closure at 12-months</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Successful Closure by Core Lab Adjudicated Transcranial Doppler (TCD) Grade &lt;= 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Migraine Disability Assessment (MIDAS) Score From Baseline to 12-months</measure>
    <time_frame>12 months</time_frame>
    <description>The MIDAS questionnaire measure the impact of headaches on daily living. A total score of 0-5 equals little to no disability, 6-10 equals mild disability, 11-20 equals moderate disability, and a score 21 or greater equals severe disability. The maximum possible score is 276.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of a 75% Reduction in Migraine Headache Attacks</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>12 months</time_frame>
    <description>Procedural success is calculated by the percent of device group subjects who were implanted with the study device and experienced no serious device or procedure-related adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-Term Success</measure>
    <time_frame>12 months</time_frame>
    <description>Percent of PFO closure group subjects who were implanted with the study device, experienced no serious device or procedure-related adverse events and have a core-lab adjudicated TCD Grade at Valsalva â‰¤ 2 at 1-year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All Adverse Events at 12-months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Device-related Adverse Events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of a 95% Reduction in Migraine Headache Attacks</measure>
    <time_frame>12-months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Beck Depression Inventory (BDI) Scale</measure>
    <time_frame>12 months</time_frame>
    <description>The difference in BDI between baseline and 12-months for the respective randomization groups. The highest possible score of the BDI is 63, which represents extreme depression. The lowest possible score is 0, which represents no depression.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Migraine Headaches</condition>
  <condition>Patent Foramen Ovale</condition>
  <arm_group>
    <arm_group_label>Medical Management</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PFO Closure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and undergo PFO device closure procedure with the AMPLATZER PFO Occluder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <description>Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure). Participants completing 1 year follow-up are eligible for PFO closure with the AMPLATZER PFO Occluder.</description>
    <arm_group_label>Medical Management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AMPLATZER PFO Occluder</intervention_name>
    <description>Patients in this arm will receive the AMPLATZER PFO Occluder device</description>
    <arm_group_label>PFO Closure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects diagnosed as having migraine headaches both with and without aura&#xD;
&#xD;
          -  Have a Patent Foramen Ovale (PFO)&#xD;
&#xD;
          -  A migraine history and show a refractoriness to medical treatment&#xD;
&#xD;
          -  Willing to participate in follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects whose primary headaches are other than migraine headaches&#xD;
&#xD;
          -  Who overuse migraine treatments&#xD;
&#xD;
          -  With a clinical history of stroke or Transient Ischemic Attack (TIA)&#xD;
&#xD;
          -  With contraindication to aspirin therapy and Clopidogrel&#xD;
&#xD;
          -  Pregnant or desire to become pregnant within the next year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherman Sorensen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Silberstein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Tobis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Charles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital &amp; Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Rockies</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Cloud Hospital</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johns's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alegent Health Bergan Mercy Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Heart Center Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical School</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-8679</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Hospitals</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mark's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Healthcare Services</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2006</study_first_posted>
  <results_first_submitted>May 2, 2016</results_first_submitted>
  <results_first_submitted_qc>July 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2020</results_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>PFO</keyword>
  <keyword>Migraine Headache</keyword>
  <keyword>patent foramen ovale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>60 day baseline diary completion prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sham Procedure</title>
          <description>Did not receive the closure device, and treated with the current standard of care medical treatment.</description>
        </group>
        <group group_id="P2">
          <title>Patent Foramen Ovale (PFO) Device Closure</title>
          <description>Patent foramen ovale (PFO) device Closure procedure using the AMPLATZER PFO Occluder device.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early Termination</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Optional Patent Foramen Ovale Closure</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">A sham procedure was not part of this period.</participants>
                <participants group_id="P2" count="87">Participants who completed Sham Procedure randomization Arm were eligible. 87/103 consented.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sham Procedure</title>
          <description>Participants will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure).</description>
        </group>
        <group group_id="B2">
          <title>PFO Device Closure</title>
          <description>Participants will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and undergo PFO device closure procedure with the AMPLATZER PFO Occluder.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="107"/>
            <count group_id="B2" value="123"/>
            <count group_id="B3" value="230"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.72" spread="10.16"/>
                    <measurement group_id="B2" value="42.75" spread="10.27"/>
                    <measurement group_id="B3" value="43.20" spread="10.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Classification of Headache Disorders (ICH)</title>
          <description>Participants can have more than one International Classification of Headache Disorder, which is why the sum of the three categories exceeds the overall number of baseline participants.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Migraine with Aura (ICH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine without Aura (ICH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine with and without Aura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy Endpoint - Percentage of Subjects With a 50% Reduction From Baseline in the Monthly Number of Migraine Attacks at 12 Months.</title>
        <description>A 50% reduction from the monthly number of migraine attacks during the 60-day baseline phase to the monthly number of migraine attacks during month ten through the twelfth month in the treatment phase (device group versus sham group).</description>
        <time_frame>Baseline and months 10-12</time_frame>
        <population>Participants included in the analysis were followed for 1-year, had Clinical Event Committee (CEC) adjudicated headache diaries, had greater than or equal to 60% diary compliance during the treatment phase (10-12 months) and were not treatment failures.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Procedure</title>
            <description>Did not receive the closure device, and treated with the current standard of care medical treatment.</description>
          </group>
          <group group_id="O2">
            <title>PFO Device Closure</title>
            <description>PFO device Closure procedure using the AMPLATZER PFO Occluder device.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy Endpoint - Percentage of Subjects With a 50% Reduction From Baseline in the Monthly Number of Migraine Attacks at 12 Months.</title>
          <description>A 50% reduction from the monthly number of migraine attacks during the 60-day baseline phase to the monthly number of migraine attacks during month ten through the twelfth month in the treatment phase (device group versus sham group).</description>
          <population>Participants included in the analysis were followed for 1-year, had Clinical Event Committee (CEC) adjudicated headache diaries, had greater than or equal to 60% diary compliance during the treatment phase (10-12 months) and were not treatment failures.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Endpoint - Device Related Serious Adverse Event (SAE)</title>
        <description>Number of subjects who experience a device-related major adverse event (DRMAE) through 12-months of follow-up.&#xD;
This endpoint was analyzed using an as-treated cohort that consists of all enrolled subjects who received the device (randomized and Optional PFO Closure group) and who had follow-up sufficient to adequately assess the DRMAE rate.</description>
        <time_frame>Baseline through 12 months</time_frame>
        <population>All enrolled subjects who received the device (randomized and Optional PFO Closure group). 5 subjects were considered to have insufficient follow-up and were therefore excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PFO Device Closure</title>
            <description>PFO device Closure procedure using the AMPLATZER PFO Occluder device.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Endpoint - Device Related Serious Adverse Event (SAE)</title>
          <description>Number of subjects who experience a device-related major adverse event (DRMAE) through 12-months of follow-up.&#xD;
This endpoint was analyzed using an as-treated cohort that consists of all enrolled subjects who received the device (randomized and Optional PFO Closure group) and who had follow-up sufficient to adequately assess the DRMAE rate.</description>
          <population>All enrolled subjects who received the device (randomized and Optional PFO Closure group). 5 subjects were considered to have insufficient follow-up and were therefore excluded from the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>99% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" lower_limit="0.01" upper_limit="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Migraine Days/Month</title>
        <description>Change in the number of migraine days is calculated by the difference in the mean number of migraine days between the baseline assessment period and the treatment phase (months 10-12 post-procedure) for the respective randomization groups.</description>
        <time_frame>Baseline and months 10-12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham Procedure</title>
            <description>Sham Procedure and treated only with current standard of care medical treatment.</description>
          </group>
          <group group_id="O2">
            <title>PFO Device Closure</title>
            <description>Patients in this arm received the AMPLATZER PFO Occluder device</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Migraine Days/Month</title>
          <description>Change in the number of migraine days is calculated by the difference in the mean number of migraine days between the baseline assessment period and the treatment phase (months 10-12 post-procedure) for the respective randomization groups.</description>
          <units>Migraine days per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="5.0"/>
                    <measurement group_id="O2" value="3.4" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Successful PFO Closure at 12-months</title>
        <description>Successful Closure by Core Lab Adjudicated Transcranial Doppler (TCD) Grade &lt;= 2</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>117 device subjects completed the 12 month visit. Only 104 had TCDs that were able to be adjudicated. Of the 13 device subjects with unadjudicated TCDs, 4 did not have valsalva data and 9 did not have TCD data available for various reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>PFO Closure</title>
            <description>Device group subjects who had a Core Lab adjudicated TCD grade at Valsalva of less than or equal to 2 at 12-months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Successful PFO Closure at 12-months</title>
          <description>Successful Closure by Core Lab Adjudicated Transcranial Doppler (TCD) Grade &lt;= 2</description>
          <population>117 device subjects completed the 12 month visit. Only 104 had TCDs that were able to be adjudicated. Of the 13 device subjects with unadjudicated TCDs, 4 did not have valsalva data and 9 did not have TCD data available for various reasons.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" lower_limit="74" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Migraine Disability Assessment (MIDAS) Score From Baseline to 12-months</title>
        <description>The MIDAS questionnaire measure the impact of headaches on daily living. A total score of 0-5 equals little to no disability, 6-10 equals mild disability, 11-20 equals moderate disability, and a score 21 or greater equals severe disability. The maximum possible score is 276.</description>
        <time_frame>12 months</time_frame>
        <population>101 participants in the sham group and 116 subjects in the PFO device closure group had both baseline and 12-month MIDAS scores available to perform the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Procedure</title>
            <description>Sham Procedure and treated only with current standard of care medical treatment.</description>
          </group>
          <group group_id="O2">
            <title>PFO Device Closure</title>
            <description>Patients in this arm received the AMPLATZER PFO Occluder device</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Migraine Disability Assessment (MIDAS) Score From Baseline to 12-months</title>
          <description>The MIDAS questionnaire measure the impact of headaches on daily living. A total score of 0-5 equals little to no disability, 6-10 equals mild disability, 11-20 equals moderate disability, and a score 21 or greater equals severe disability. The maximum possible score is 276.</description>
          <population>101 participants in the sham group and 116 subjects in the PFO device closure group had both baseline and 12-month MIDAS scores available to perform the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17" spread="36"/>
                    <measurement group_id="O2" value="-22.6" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of a 75% Reduction in Migraine Headache Attacks</title>
        <time_frame>12 months</time_frame>
        <population>Participants were included in the analysis were followed for 1-year, have CEC adjudicated headache diaries, had greater than or equal to 60% diary compliance during the treatment phase (10-12 months) and were not treatment failures.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Procedure</title>
            <description>Sham Procedure and treated only with current standard of care medical treatment.</description>
          </group>
          <group group_id="O2">
            <title>PFO Device Closure</title>
            <description>Patients in this arm received the AMPLATZER PFO Occluder device</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of a 75% Reduction in Migraine Headache Attacks</title>
          <population>Participants were included in the analysis were followed for 1-year, have CEC adjudicated headache diaries, had greater than or equal to 60% diary compliance during the treatment phase (10-12 months) and were not treatment failures.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Procedural success is calculated by the percent of device group subjects who were implanted with the study device and experienced no serious device or procedure-related adverse events.</description>
        <time_frame>12 months</time_frame>
        <population>Device group subjects who were implanted with the study device and experienced no serious device or procedure-related adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>PFO Closure</title>
            <description>Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and undergo PFO device closure procedure with the AMPLATZER PFO Occluder.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Procedural success is calculated by the percent of device group subjects who were implanted with the study device and experienced no serious device or procedure-related adverse events.</description>
          <population>Device group subjects who were implanted with the study device and experienced no serious device or procedure-related adverse events.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3" lower_limit="88.6" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-Term Success</title>
        <description>Percent of PFO closure group subjects who were implanted with the study device, experienced no serious device or procedure-related adverse events and have a core-lab adjudicated TCD Grade at Valsalva â‰¤ 2 at 1-year.</description>
        <time_frame>12 months</time_frame>
        <population>Percent of PFO closure group subjects who were implanted with the study device, experienced no serious device or procedure-related adverse events and have a core-lab adjudicated TCD Grade at Valsalva â‰¤ 2 at 1-year. 117 device subjects completed the 12 month visit. Only 104 had TCDs that were able to be adjudicated.</population>
        <group_list>
          <group group_id="O1">
            <title>PFO Closure</title>
            <description>Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and undergo PFO device closure procedure with the AMPLATZER PFO Occluder.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-Term Success</title>
          <description>Percent of PFO closure group subjects who were implanted with the study device, experienced no serious device or procedure-related adverse events and have a core-lab adjudicated TCD Grade at Valsalva â‰¤ 2 at 1-year.</description>
          <population>Percent of PFO closure group subjects who were implanted with the study device, experienced no serious device or procedure-related adverse events and have a core-lab adjudicated TCD Grade at Valsalva â‰¤ 2 at 1-year. 117 device subjects completed the 12 month visit. Only 104 had TCDs that were able to be adjudicated.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" lower_limit="71.9" upper_limit="87.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All Adverse Events at 12-months</title>
        <time_frame>12 months</time_frame>
        <population>Participants who experienced an adverse event at or before 12-months post-procedure</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Procedure</title>
            <description>Sham Procedure and treated only with current standard of care medical treatment.</description>
          </group>
          <group group_id="O2">
            <title>PFO Device Closure</title>
            <description>Patients in this arm received the AMPLATZER PFO Occluder device</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All Adverse Events at 12-months</title>
          <population>Participants who experienced an adverse event at or before 12-months post-procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Device-related Adverse Events</title>
        <time_frame>12 months</time_frame>
        <population>Participants who experienced a device-related adverse event, as adjudicated by the Data Safety and Monitoring Board (DSMB), at or before 12-months post-procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>PFO Closure</title>
            <description>Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and undergo PFO device closure procedure with the AMPLATZER PFO Occluder.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Device-related Adverse Events</title>
          <population>Participants who experienced a device-related adverse event, as adjudicated by the Data Safety and Monitoring Board (DSMB), at or before 12-months post-procedure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" lower_limit="23.6" upper_limit="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of a 95% Reduction in Migraine Headache Attacks</title>
        <time_frame>12-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham Procedure</title>
            <description>Sham Procedure and treated only with current standard of care medical treatment.</description>
          </group>
          <group group_id="O2">
            <title>PFO Device Closure</title>
            <description>Patients in this arm received the AMPLATZER PFO Occluder device</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of a 95% Reduction in Migraine Headache Attacks</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97"/>
                    <measurement group_id="O2" value="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Beck Depression Inventory (BDI) Scale</title>
        <description>The difference in BDI between baseline and 12-months for the respective randomization groups. The highest possible score of the BDI is 63, which represents extreme depression. The lowest possible score is 0, which represents no depression.</description>
        <time_frame>12 months</time_frame>
        <population>101 participants in the sham group and 116 subjects in the PFO device closure group had both baseline and 12-month BDI scores available to perform the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Procedure</title>
            <description>Sham Procedure and treated only with current standard of care medical treatment.</description>
          </group>
          <group group_id="O2">
            <title>PFO Device Closure</title>
            <description>Patients in this arm received the AMPLATZER PFO Occluder device</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Beck Depression Inventory (BDI) Scale</title>
          <description>The difference in BDI between baseline and 12-months for the respective randomization groups. The highest possible score of the BDI is 63, which represents extreme depression. The lowest possible score is 0, which represents no depression.</description>
          <population>101 participants in the sham group and 116 subjects in the PFO device closure group had both baseline and 12-month BDI scores available to perform the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="7.1"/>
                    <measurement group_id="O2" value="-2.1" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Responder Rate for Subjects in Whom Majority of Attacks Were With Aura</title>
        <description>The term &quot;majority&quot; in &quot;majority of migraine attacks included aura&quot; was defined by the Neurologist (&gt;50%) at the time of randomization based on a review of the subject's study baseline headache diary and medical history.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PFO Device Closure</title>
            <description>Patients in this arm received the AMPLATZER PFO Occluder device.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Sham Procedure and treated only with current standard of care medical treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate for Subjects in Whom Majority of Attacks Were With Aura</title>
          <description>The term &quot;majority&quot; in &quot;majority of migraine attacks included aura&quot; was defined by the Neurologist (&gt;50%) at the time of randomization based on a review of the subject's study baseline headache diary and medical history.</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7"/>
                    <measurement group_id="O2" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percentage of Subjects With Migraine With Aura Determined to Have a Complete Cessation of Migraine Attacks According to the International Headache Society (IHS)</title>
        <description>Complete Cessation of Migraine Attacks, baseline diary compared to months 10-12</description>
        <time_frame>Baseline through months 10-12</time_frame>
        <population>6 PFO Device Closure Subjects and 3 Sham Procedure Subjects with Aura do not have 12-month follow-up data available.</population>
        <group_list>
          <group group_id="O1">
            <title>PFO Device Closure</title>
            <description>Patients in this arm received the AMPLATZER PFO Occluder device.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Sham Procedure and treated only with current standard of care medical treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Migraine With Aura Determined to Have a Complete Cessation of Migraine Attacks According to the International Headache Society (IHS)</title>
          <description>Complete Cessation of Migraine Attacks, baseline diary compared to months 10-12</description>
          <population>6 PFO Device Closure Subjects and 3 Sham Procedure Subjects with Aura do not have 12-month follow-up data available.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were collected from the time of signing informed consent until the 12-month follow-up visit. After the 12-month follow-up visit, serious adverse events and/or device-related events were collected until completion of study requirements.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PFO Device Closure</title>
          <description>PFO device Closure procedure using the AMPLATZER PFO Occluder device.</description>
        </group>
        <group group_id="E2">
          <title>Sham Procedure</title>
          <description>Did not receive the closure device, and treated with the current standard of care medical treatment.</description>
        </group>
        <group group_id="E3">
          <title>Optional PFO Closure</title>
          <description>Subjects randomized to the sham arm and completed their 12-month follow up visit were given the option of PFO closure with the Amplatzer PFO Occluder.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Transient atrial fibrillation after device placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Hypertension/Hypertension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="31" subjects_affected="30" subjects_at_risk="123"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="107"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="123"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Fatigue/Generalized Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="123"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="35" subjects_affected="29" subjects_at_risk="123"/>
                <counts group_id="E2" events="40" subjects_affected="23" subjects_at_risk="107"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="123"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="107"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Bruise/Purpura Simplex</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="123"/>
                <counts group_id="E2" events="31" subjects_affected="27" subjects_at_risk="107"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Viral Syndrome</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Low Back Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Mid-Sternal Chest Pressure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Common cold/Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="35" subjects_affected="29" subjects_at_risk="123"/>
                <counts group_id="E2" events="39" subjects_affected="28" subjects_at_risk="107"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="123"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="107"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Access Site Complication Pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="123"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="107"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Vascular Access Site Complication Hematoma</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="107"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Vascular Access Site Complication Bruise</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Vascular Access Site Complication Bleeding</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Global Clinical Affairs</name_or_title>
      <organization>St. Jude Medical</organization>
      <phone>818-493-3648</phone>
      <email>aoza@sjm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

